'Positive surprise' for Biogen in lupus, but all eyes on CTAD data this week

Biogen is joining AstraZeneca on a strong positive for its lupus candidates as the pair face going head-to-head on the market.

Biogen, which is also being closely watched for its Alzheimer’s phoenix from the flames drug data out this Thursday at the Clinical Trials on Alzheimer's Disease meeting, quietly announced positive phase 2 data in lupus this morning, a rare win in the field and for the biotech of late.